Begin main content

Trimebutine Maleate and Pinaverium Bromide for Irritable Bowel Syndrome: A Review of the Clinical Effectiveness, Safety and Guidelines

Last updated: November 30, 2015
Project Number: RC0721-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report

Question

  1. What is the clinical effectiveness and safety of trimebutine maleate for the treatment of patients with irritable bowel syndrome?
  2. What is the clinical effectiveness and safety of pinaverium bromide for the treatment of patients with irritable bowel syndrome?
  3. What are the evidence-based guidelines for the use of trimebutine maleate and pinaverium bromide for the treatment of irritable bowel syndrome?

Key Message

Evidence suggests that compared with placebo there may be improvement in abdominal pain with trimebutine or pinaverium treatment for adult patients with irritable bowel syndrome (IBS), however results were not always statistically significant. Findings from single RCTs suggest improvement in stool consistency and frequency with trimebutine or pinaverium treatment. Adverse effects with trimebutine or pinavarium appeared to be few, however not many studies reported on adverse effects. No evidence-based guidelines were identified for the use of trimebutine and pinaverium for the treatment of irritable bowel syndrome.